Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,799 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06330064RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07701993RecruitingPhase 3
Testing efimosfermin for MASH with compensated cirrhosis
This trial tests whether efimosfermin, an experimental drug, can safely help people with MASH (a fatty liver disease) that has led to cirrhosis (liver scarring) but the liver is still working well (compensated). Participants will be randomly assigned to receive the drug or a placebo.
Miami, FloridaAges 18–75 - NCT06506643RecruitingPhase 1/Phase 2
Study of KLS-1 for solid tumors and CLL
This trial tests a new drug called KLS-1 for people with solid tumors (like melanoma, pancreatic, or prostate cancer) or chronic lymphocytic leukemia (CLL) that is no longer responding to standard treatments. The goal is to see if KLS-1 is safe and can shrink tumors or slow the cancer.
KropyvnytskyiAges 18 years+ - NCT07564141RecruitingPhase 3
New Drug for Recurrent Ovarian Cancer After Chemotherapy
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Danbury, ConnecticutAges 18 years+ - NCT07587125RecruitingPhase 1
CAR-T Cell Therapy for Progressive Multiple Sclerosis
This trial tests a new cell therapy called S103 for people with MS that isn't responding well to standard treatments. The therapy involves modifying immune cells in the lab and putting them back into your body to help control the disease.
Xi'an, ShaanxiAges 18–75 - NCT07645924RecruitingPhase 3
Testing a New Migraine Treatment: Elismetrep
This study tests whether a new drug called elismetrep can quickly relieve migraine headaches when taken during an attack. If you have frequent moderate-to-severe migraines, this trial may help you find relief and contribute to better migraine treatments.
Birmingham, AlabamaAges 18–75 - NCT07704892RecruitingPhase 3
Study of efimosfermin for adults with cirrhosis from MASH
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
Miami, FloridaAges 18–75 - NCT07594119RecruitingPhase 3
Testing RAP-219 to reduce seizures in focal epilepsy
This study tests a new medication called RAP-219 to see if it can reduce seizure frequency in adults with focal epilepsy (seizures starting in one area of the brain). You'll take the medication alongside your current seizure drugs and track your seizures daily using an app.
Bentonville, ArkansasAges 18–75 - NCT06289478Recruiting
Tranexamic acid for bleeding during hip replacement surgery
This study tests whether a medicine called tranexamic acid (TXA), given as a shot into the hip joint or as a soak on the skin, can reduce bleeding during hip replacement surgery. It is for people over 60 who broke their hip from a simple fall and need a cementless hip replacement.
Bangkok, BangkokAges 60 years+ - NCT06902558RecruitingPhase 2
Study of ABBV-CLS-628 for adults with polycystic kidney disease
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
Birmingham, AlabamaAges 18–55 - NCT07220785RecruitingPhase 3
Testing mibavademab for generalized lipodystrophy in adults and children
This trial tests a new drug called mibavademab for people with generalized lipodystrophy, a condition where the body can't store fat properly, leading to problems like diabetes and high triglycerides. It aims to see if the drug safely improves these metabolic issues.
Ann Arbor, MichiganAges 2 years+ - NCT06419374RecruitingPhase 3
Testing a new drug for liver scarring from MASH
This trial tests a new drug called pegozafermin to see if it can help people with cirrhosis (scarring) of the liver caused by MASH (a fatty liver disease). If you have cirrhosis and either diabetes or multiple risk factors, this study might be an option for you.
Birmingham, AlabamaAges 18–75 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT07019922RecruitingPhase 3
A study of elsunersen for children with SCN2A-related epilepsy
This trial tests an experimental drug called elsunersen in children with a specific type of epilepsy caused by changes in the SCN2A gene. It aims to see if the drug can reduce seizures and be safe for children.
San Diego, CaliforniaAges 1 day–18 years - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT07137910RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
Beijing, Beijing MunicipalityAges 18–65 - NCT07747103RecruitingPhase 3
Porcine thyroid extract for hypothyroidism
This trial tests a new porcine (pig) thyroid hormone replacement tablet for people with primary hypothyroidism (underactive thyroid). It aims to see if this treatment is safe and effective compared to current levothyroxine therapy.
Modesto, CaliforniaAges 18–75 - NCT07381634RecruitingPhase 2
Testing ondansetron to reduce immunotherapy side effects in liver cancer
This study tests whether adding ondansetron (a common anti-nausea drug) can reduce side effects from immunotherapy in people with liver cancer. If you are starting a specific combination treatment for liver cancer, you may be eligible.
Wenzhou, ZhejiangAges 18–80 - NCT06944522RecruitingPhase 3
Cell therapy for Parkinson's symptoms
This study tests a new cell therapy called bemdaneprocel to see if it can reduce Parkinson's symptoms and “off” time. The treatment involves transplanting special cells into the brain to help replace lost dopamine-producing cells.
Scottsdale, ArizonaAges 45–75 - NCT07662109RecruitingPhase 3
Testing a new combo pill for type 2 diabetes
This study tests if a new medicine (elecoglipron) combined with dapagliflozin is safe and works better for adults with type 2 diabetes that isn't well controlled by diet or other medications.
Huntsville, AlabamaAges 18 years+ - NCT07742735RecruitingPhase 3
Study of apraglutide for short bowel syndrome with intestinal failure
This study tests a new medicine called apraglutide, given as a shot, to see if it can help adults with short bowel syndrome and intestinal failure reduce their need for intravenous nutrition (parenteral support). The study compares apraglutide to a placebo (a shot with no medicine) to check if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT07662135RecruitingPhase 3
A study of elecoglipron for type 2 diabetes with kidney problems
This trial tests a new medicine called elecoglipron to see if it helps control blood sugar in people with type 2 diabetes who also have reduced kidney function. You would continue taking your current SGLT2i medication (like dapagliflozin).
Peoria, ArizonaAges 18 years+ - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Fountain Valley, CaliforniaAges 18 years+ - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Mobile, AlabamaAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,799 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.